PMID- 34196973
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20211002
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 35
IP  - 5
DP  - 2021 Sep
TI  - Clinical safety of robenacoxib in cats with chronic musculoskeletal disease.
PG  - 2384-2394
LID - 10.1111/jvim.16148 [doi]
AB  - BACKGROUND: Evaluate the clinical safety of robenacoxib in cats with chronic 
      musculoskeletal disease (CMSD). ANIMALS: Four hundred forty-nine client-owned 
      cats with CMSD. METHODS: Pooled analysis of safety variables from 4 prospective 
      randomized blinded clinical trials of robenacoxib (n = 222) versus placebo 
      (n = 227), administered orally once daily for 4 to 12 weeks. Safety was evaluated 
      from reported adverse events (AEs) and abnormalities detected on hematology and 
      serum and urine chemistry analyses. RESULTS: The number of cats with at least 1 
      AE was not significantly different (P = .15) with robenacoxib (n = 106, 47.8%) 
      compared to placebo (n = 93, 41.0%). The relative risk of at least 1 AE 
      (incidence robenacoxib/placebo) was 1.15 (95% confidence interval 0.93-1.43). 
      There was no significant difference between groups in the number of clinical 
      signs (range, 0-9) per cat (P = .23). Serum creatinine concentrations were higher 
      during robenacoxib administration compared to placebo (+4.36 mumol/L, 95% 
      confidence interval 0.21-8.50), but no related adverse clinical effects were 
      detected. In the subgroup of 126 cats with evidence of chronic kidney disease, 
      the relative risk of at least 1 AE (robenacoxib/placebo) was 1.09 (95% confidence 
      interval 0.78-1.52, P = .61). CONCLUSIONS AND CLINICAL IMPORTANCE: Robenacoxib 
      was not associated with increased risk of AEs compared to placebo when 
      administered for 4 to 12 weeks to cats with CMSD. The generalizability of the 
      results to general practice is limited by the fact that cases with severe and 
      uncontrolled concomitant diseases were not included.
CI  - (c) 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley 
      Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
FAU - King, Jonathan N
AU  - King JN
AUID- ORCID: 0000-0002-4194-9015
AD  - Elanco Animal Health, Companion Animal Development, Basel, Switzerland.
FAU - Seewald, Wolfgang
AU  - Seewald W
AD  - Elanco Animal Health, Companion Animal Development, Basel, Switzerland.
FAU - Forster, Sophie
AU  - Forster S
AUID- ORCID: 0000-0001-9991-5531
AD  - Elanco Animal Health, Companion Animal Development, Basingstoke, UK.
FAU - Friton, Gabriele
AU  - Friton G
AUID- ORCID: 0000-0003-2654-6717
AD  - Elanco Animal Health, Companion Animal Development, Basel, Switzerland.
FAU - Adrian, Derek E
AU  - Adrian DE
AUID- ORCID: 0000-0002-0226-6182
AD  - Translational Research in Pain Program, Department of Clinical Sciences, College 
      of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, 
      USA.
AD  - Comparative Pain Research and Education Center, North Carolina State University, 
      Raleigh, North Carolina, USA.
FAU - Lascelles, B Duncan X
AU  - Lascelles BDX
AUID- ORCID: 0000-0002-2950-9009
AD  - Translational Research in Pain Program, Department of Clinical Sciences, College 
      of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, 
      USA.
AD  - Comparative Pain Research and Education Center, North Carolina State University, 
      Raleigh, North Carolina, USA.
AD  - Thurston Arthritis Center, UNC School of Medicine, Chapel Hill, North Carolina, 
      USA.
AD  - Center for Translational Pain Research, Department of Anesthesiology, Duke 
      University, Durham, North Carolina, USA.
LA  - eng
PT  - Journal Article
DEP - 20210701
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Phenylacetates)
RN  - 9N3CBB0BIQ (Diphenylamine)
RN  - Z588009C7C (robenacoxib)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - *Cat Diseases/drug therapy
MH  - Cats
MH  - Diphenylamine/adverse effects/analogs & derivatives
MH  - *Musculoskeletal Diseases/drug therapy/veterinary
MH  - Phenylacetates
MH  - Prospective Studies
PMC - PMC8478032
OTO - NOTNLM
OT  - NSAID
OT  - adverse event
OT  - coxib
OT  - harm
COIS- The studies were supported by Novartis Animal Health, now owned by Elanco Animal 
      Health, which manufactures and distributes robenacoxib (Onsior). Jonathan N. 
      King, Sophie Forster and Gabriele Friton are employed by, and Wolfgang Seewald is 
      retired from, Elanco Animal Health. Derek E. Adrian was employed by North 
      Carolina State University during the study, but has subsequently joined Elanco 
      Animal Health. B. Duncan X. Lascelles received payment from Elanco Animal Health 
      in the past 5 years for consultancy and speaking engagements.
EDAT- 2021/07/02 06:00
MHDA- 2021/10/01 06:00
PMCR- 2021/09/01
CRDT- 2021/07/01 12:31
PHST- 2020/05/13 00:00 [received]
PHST- 2021/04/23 00:00 [accepted]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2021/07/01 12:31 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - JVIM16148 [pii]
AID - 10.1111/jvim.16148 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2021 Sep;35(5):2384-2394. doi: 10.1111/jvim.16148. Epub 2021 
      Jul 1.